INFLUENCE OF SECONDARY HYPERPARATHYROIDISM ON THE CALCIFICATION OF HEART VALVES IN PATIENTS WITH CHRONIC KIDNEY DISEASE VD STAGE

V. Lesovoy; N. Andonieva; T. Valkovskaya

doi:10.31450/ukrjnd.3(55).2017.09

V. Lesovoy Kharkov regional center of urology and nephrology n. a. V. I. Shapoval
N. Andonieva Kharkov regional center of urology and nephrology n. a. V. I. Shapoval
T. Valkovskaya Kharkov regional center of urology and nephrology n. a. V. I. Shapoval

DOI: https://doi.org/10.31450/ukrjnd.3(55).2017.09

Keywords: chronic kidney disease V D stage, haemodialysis, peritoneal dialysis, hyperparathyroidism, calcification of heart valves

Abstract

The aim of this work was to study the relationship of elevated levels of parathyroid hormone (PTH) with cardiovascular changes (calcification of the heart valves) and to identify possible risk factors of calcification in the group of patients receiving renal replacement therapy.

Materials and methods. The study included 96 patients with ESRD: 1-st group receives the treatment of peritoneal dialysis (PD) (45 patients), 2-nd group haemodialysis (HD) (51 patients). In serum determined concentration of calcium, phosphorus, PTH. All patients underwent echocardiographic examination.

Results. The prevalence of secondary hyperparathyroidism in PD-patients reached 72%, in HD-patients 83%. Calcification of heart valves in both groups occurred in patients with high PTH level (greater than 400 PG/ml). Patients in both groups were significantly more frequent in the combined mitrale-aortic calcification. Isolated mitral calcification was detected more often aortic. Predictors of progression of calcification of heart valves in patients on PD is the age, in patients on HD - level average BP and the duration of dialysis therapy.

Conclusions. Echocardiological data and clinical and laboratory examination of patients with ESRD allowed us to estimate the prevalence and structure of mitrale-aortic calcification and its relationship with secondary hyperparathyroidism.

Downloads

Download data is not yet available.

References

Волгина Г. В. Паратиреоидный гормон - универсалный уремический токсин // Нефрология и диализ. – 2000. – Т.2. – № 1-2. – С. 32-38.

Волгина Г., Селезеёв Д., Балкарова О. Внекостная кальцификация у пациентов с хронической болезнью почек // Врач. – 2012. – № 7. – С.2-8.

Добронравов В. А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Kloto // Нефрология. – 2013. – Т.15 – №4. – C. 11-20.

Земченков А. Ю., Герасимчук Р. П. Сосудистая кальцификация и активаторы рецепторов витамина D. Обзор // Нефрология и диализ. – 2011. – Т. 11. – №4.

Новикова Н.А., Гендлин Г.Е., Эттингер О. А. и др. Взаимосвязь артериальной гипертензии и изменений гемодинамики у больных с хронической почечной недостаточностью, получающих лечение перитонеальным диализом // Нефрология и диализ. – 2008. – Т.10. – №1. – С.44-51.

Суворов А.В., Зубеева Г.Н., Обухова С.В. Влияние значений артериального давления на прогноз и выживаемость диализных пациентов // Современные технологии в медицине. – 2012. – №2. – С. 135-137.

Щеголев А.А. Вторичный гиперпаратиреоз при хронической почечной недостаточности / А. А. Щеголев, П. Я.Филипцев, А. А. Ларин, В. В. Пляшин, С. А. Сокольский, М. А. Коган, Н. Б. Голованова, О. Б. Когут, Е. Н. Хитрова // Журнал Лечебное дело. – 2009. – С.75-80.

Adragao T., Pires A., Lucas C. et al. ‘A simple vascular calcification score predicts cardio-vascular risk in haemodialysis patients’. Nephrol. Dial. Transplant — 2008. — vol. 19, №6 — P. 1480-1488.

Amman K. ‘Media calcification and intimal calcification are district entitiens in chronic kidney disease’. Clin. J. Am. Soc. Nephrol. - 2010. -vol.3, №6. - P. 1566- 1604.

Baldini V., Mastropasqua M., Francucci С. M., Erasmo E. D. ‘Cardiovascular disease and osteoporosis’ J. Endocrinol Invest. - 2010. — vol.28 Suppl. 10-P. 69-72.